3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Small Cell Lung Carcinoma
23
Breast Neoplasms
17
Sarcoma
16
Carcinoma, Hepatocellular
10
Lung Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Stomach Neoplasms
8
Neoplasms
8
Triple Negative Breast Neoplasms
7
Ovarian Neoplasms
7
Nasopharyngeal Carcinoma
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
NSCLC
5
Colorectal Neoplasms
5
Carcinoma
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
4
Pheochromocytoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Recurrence
3
Paraganglioma
3
Non-squamous Non-small Cell Lung Cancer
3
Glioma
3
Fallopian Tube Neoplasms
3
Cholangiocarcinoma
3
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
liposomal doxorubicin
4
Temozolomide
4
Biopsy
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leiomyosarcoma
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled